Greenwich Pharmaceuticals Inc. (NASDAQ:GRPI) announcedWednesday that it has filed a product license application (PLA)in Britain for its drug Therafectin. The Ft. Washington, Pa.,company is developing Therafectin as a chronic treatment forrheumatoid arthritis.

(c) 1997 American Health Consultants. All rights reserved.